EGFR and neoplasm: Serial ctDNA measurements could complement routine imaging-based assessments in evaluation of disease bulk [43], response to chemotherapeutic agents, re-challenge with anti-EGFR therapy [44], and detection of residual disease after surgical resection of the tumor [45].